<DOC>
	<DOCNO>NCT01685281</DOCNO>
	<brief_summary>study objective compare efficacy , safety tolerability two dos MG01CI ( 1400 mg 700 mg ) Placebo treatment symptom adult diagnose PI-ADHD . subject randomly assign 1:1:1 ratio one three treatment sequence follow : 1. week 1:1400 mg , week 2:700 mg , week 3 : placebo 2. week 1:700 mg , week 2 : placebo , week 3:1400 mg 3. week 1 : placebo , week2:1400 mg , week 3 700 mg The study consist three period : screening period one week , 3-week double-blind treatment period , one-week safety follow-up period .</brief_summary>
	<brief_title>Study Comparing Two Doses MG01CI Placebo Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder</brief_title>
	<detailed_description>The purpose dose find study compare two dos MG01CI ( 1400 mg 700 mg ) Placebo , adult subject PI-ADHD . A crossover study design allow evaluation safety/tolerability efficacy use validated computerized test . subject randomly assign 1:1:1 ratio one three treatment sequence follow : 1. week 1:1400 mg , week 2:700 mg , week 3 : placebo 2. week 1:700 mg , week 2 : placebo , week 3:1400 mg 3. week 1 : placebo , week2:1400 mg , week 3 700 mg Overview Study Visits Screening Period : Visit 1 - Screening/Baseline Visit ( 7 day prior dose ) Treatment Period : Visit 2 - Day 0 ( Randomization Visit ) Visit 3 - Day 7 ± 3 day Visit 4 - Day 14 ± 3 day Visit 5 - Day 21 ± 3 day Follow-up period : Visit 6 - Day 28 ± 3 day Study duration subject 35 day .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Metadoxine</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<criteria>1 . Adult men woman , 18 55 year old 2 . Diagnosed predominantly inattentive ADHD base DSMIV criterion ADHD assess Adult ADHD Clinician Diagnostic Scale ( ACDS V1.2 ) ; 3 . Clinical severity least moderate level ( Clinical Global Impression score 4 ) 4 . TOVA ADHD score 1.8 Screening /Baseline 5 . Women childbearing potential must agree use effective contraceptive negative urine pregnancy test screen visit 6 . Able attend clinic regularly reliably 7 . Able swallow tablets/capsules 8 . Able understand , read , write speak Hebrew fluently complete study relate material 9 . Able understand sign write informed consent participate study 1 . Subjects ADHD otherwise specify ( NOS ) diagnosis 2 . Subjects combine type predominantly hyperactive impulsive ADHD diagnose 3 . Subjects current Axis I diagnosis SCID 4 . Subjects lifetime bipolar psychosis 5 . Subjects treatment Axis I disorder , even disorder remit 6 . Subjects nonresponders least two adequately administer ADHD treatment 7 . Subjects medical psychiatric condition common diseases hypertension , type 2 diabetes mellitus , hyperlipidemia , etc . allow per Investigator 's judgment , long stable control medical therapy constant least 8 week prior randomization throughout study 8 . Any prescription nonprescription ADHD medication 14 day ( stimulant ) 28 day ( nonstimulants psychotropics ) prior screen visit 9 . Known suspected HIVpositive advance disease AIDS , Hepatitis C , Hepatitis B tuberculosis 10 . History allergy sensitivity B complex vitamins 11 . History suspicion PDD , NLD psychotic condition 12 . Use Vitamin B throughout study ( either alone multivitamin ) 13 . Use ADHD medication throughout study 14 . Use psychotropic medication throughout study 15 . Use investigational medication/treatment past 30 day prior screen visit 16 . Use medication food supplement unless clear medical monitor 14day period randomization 17 . Current ( history within last 6 month ) drug dependence substance abuse disorder accord DSMIVTR criterion ( exclude nicotine ) . Subjects also agree refrain significantly change consumption caffeine study . 18 . Suicidality , define active ideation , intent plan , lifetime attempt ( CSSRS ) 19 . Subjects complete study instrument questionnaires 20 . Any relation Sponsor , Investigator study staff 21 . Any condition , opinion Principal Investigator would place subject risk influence conduct study interpretation result , include ( limited ) abnormally low intellectual capacity . 22 . Subjects fully comprehend implication protocol comply requirement capable follow study schedule reason 23 . Women childbearing potential must test negative pregnancy time enrollment base serum pregnancy test agree use reliable method birth control ( e.g. , oral contraceptive Norplant® ; reliable barrier method birth control [ diaphragms contraceptive jelly ; cervical cap contraceptive jelly ; condom contraceptive foam ] ; intrauterine device ; partner vasectomy ; abstinence ) study . Note inclusion criterion applies females childbearing potential . Females childbearing potential defined woman surgically sterilize menarche 2 year postmenopause</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>ADHD , Inattention</keyword>
</DOC>